Study available for Patients with DLBCL

Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma

Update: this study is closed to enrollment.

Significant progress has been made in treatment of diffuse large B-cell lymphoma (DLBCL), but some patients are still not cured of their disease. Recently, researchers have begun to understand how reversible changes in expression of genes contribute to development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed “epigenetics” since they do not involve mutations in genes themselves.

We are working to take advantage of the reversible nature of these changes by pre-treating patients with azacitidine, a drug which reverses epigenetic changes, before starting standard chemotherapy treatment. In this way, we hope to improve the sensitivity of lymphoma cells to chemotherapy.

Key eligibility:

  • Men and women age 18 and older
  • Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL)
  • Stage II, III or IV disease
  • No previous treatment
  • Detailed eligibility discussed when you contact the study team

For more information about this study, contact June Greenberg, RN at (212) 746-2651 or email June at jdg2002@med.cornell.edu.

Click here to view all our current trials for lymphoma and other cancers and blood disorders.

 

Journal Of Clinical Oncology Publishes Clinical Trial Results Of VELCADE Combination In Aggressive Subtypes Of Non-Hodgkin Lymphoma

Phase II results of a Weill Cornell-sponsored clinical trial examining VELCADE® (bortezomib) in patients with previously untreated aggressive lymphoma were published in February 2011 in the Journal of Clinical Oncology. The study was designed to examine the efficacy of VELCADE in combination with the current standard of care (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP) in 76 patients with two aggressive subtypes of lymphoma: mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL).

Dr. John Leonard, the Clinical Director of the Weill Cornell Center for Lymphoma and Myeloma, is the the principal investigator of the study. Click here to read the news release summarizing the results of the study. Click here to read the published research paper in the Journal of Clinical Oncology.

Clinical Trial for Patients with Relapsed or Refractory DLBCL

A Phase I/II study of combination epigenetic therapy with azacitidine and vorinostat in patients with relapsed and refractory DLBCL

Update: this study is closed to enrollment. 

Researchers have begun to understand how reversible changes in expression of genes contribute to the development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed “epigenetics” since they do not involve mutations in genes themselves.

In this trial we are studying a combination of 2 drugs that may work by reversing epigenetic changes in patients with diffuse large B-cell lymphoma (DLBCL) that has not responded well to chemotherapy.